What is BioLargo Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioLargo's interest expense for the
three
months ended in Dec. 2023 was $ -0.02 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.09 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioLargo's Operating Income for the
three
months ended in Dec. 2023 was $ -0.61 Mil. BioLargo's Interest Expense for the
three
months ended in Dec. 2023 was $ -0.02 Mil.
BioLargo did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
BioLargo Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLargo (OTCPK:BLGO) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
BioLargo's Interest Expense for the
three
months ended in Dec. 2023 was $-0.02 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-0.61 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $1.29 Mil.
BioLargo's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| BioLargo did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
BioLargo (BioLargo) Business Description
Traded in Other Exchanges
N/A
Address
14921 Chestnut Street, Westminster, CA, USA, 92683
BioLargo Inc invents, develops, and commercializes platform technologies to solve challenging environmental problems like PFAS contamination, advanced water, and wastewater treatment, industrial odor, and VOC control, air quality control, and infection control. The company holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. BioLargo invents or acquires novel technologies and develops them to maturity through its operating subsidiaries. It monetizes through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation, and/or the sale of the IP. The firm's technologies are commercially available and are advancing as disrupters in their respective markets.
Executives
| Linda Park |
director |
14921 CHESTNUT STREET, WESTMINSTER CA 92683 |
| Christina Elaine Bray |
director |
PO BOX 234, FREDERICK CO 80530 |
| Jack B. Strommen |
director |
7108 31ST AVENUE N., MINNEAPOLIS MN 55427 |
| Roberts Kent Charles Ii |
director |
1146 OXFORD ROAD, SAN MARINO CA 91108 |
| John S. Runyan |
director |
30001 HILLSIDE TERRACE, SAN JUAN CAPISTRANO CA 92675 |
| Dennis E Marshall |
director |
3500 W. GARRY AVENUE, SANTA ANA CA 92705 |
| Dennis P Calvert |
director, 10 percent owner, officer: Chief Executive Officer |
3500 GARRY AVE, SANTA ANA CA 92704 |
| New Millennium Capital Partners, Llc |
10 percent owner |
16333 PHOEBE AVENUE, LA MIRADA CA 90638 |
| Charles K Dargan |
officer: Chief Financial Officer |
8055 W. MANCHESTER AVE., SUITE 405, PLAYA DEL REY CA 90293 |
| Joseph L Provenzano |
director, officer: Corporate Secretary |
3500 W. GARRY AVENUE, SANTA ANA CA 92704 |
| Iowc Technologies, Inc. |
10 percent owner |
2603 MAIN STREET, SUITE 1155, IRVINE CA 92614 |
| Kenneth Reay Code |
10 percent owner |
16150 HERON AVENUE, LA MIRADA CA 90638 |
| Gary Adrian Cox |
director |
3500 W. GARRY AVENUE, SANTA ANA CA 92705 |
| Steven V Harrison |
director |
|
| Eduardo Ruiz |
director, 10 percent owner |
|
BioLargo (BioLargo) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BLGO has been successfully added to your 